BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

161 related articles for article (PubMed ID: 38236451)

  • 1. Synergistic effect of a nonsteroidal anti-inflammatory drug in combination with topotecan on small cell lung cancer cells.
    Yanar S; Kanli A; Kasap M; Bal Albayrak MG; Eskiler GG; Ozkan AD
    Mol Biol Rep; 2024 Jan; 51(1):145. PubMed ID: 38236451
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synergistic antitumor effect between vorinostat and topotecan in small cell lung cancer cells is mediated by generation of reactive oxygen species and DNA damage-induced apoptosis.
    Bruzzese F; Rocco M; Castelli S; Di Gennaro E; Desideri A; Budillon A
    Mol Cancer Ther; 2009 Nov; 8(11):3075-87. PubMed ID: 19887547
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical relevance of human cancer xenografts as a tool for preclinical assessment: example of in-vivo evaluation of topotecan-based chemotherapy in a panel of human small-cell lung cancer xenografts.
    Némati F; Daniel C; Arvelo F; Legrier ME; Froget B; Livartowski A; Assayag F; Bourgeois Y; Poupon MF; Decaudin D
    Anticancer Drugs; 2010 Jan; 21(1):25-32. PubMed ID: 19823076
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Proteomics analysis of meclofenamic acid-treated small cell lung carcinoma cells revealed changes in cellular energy metabolism for cancer cell survival.
    Yanar S; Kasap M; Kanli A; Akpinar G; Sarihan M
    J Biochem Mol Toxicol; 2023 Apr; 37(4):e23289. PubMed ID: 36536497
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Topotecan synergizes with CHEK1 (CHK1) inhibitor to induce apoptosis in ovarian cancer cells.
    Kim MK; James J; Annunziata CM
    BMC Cancer; 2015 Mar; 15():196. PubMed ID: 25884494
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines.
    Kaufmann SH; Peereboom D; Buckwalter CA; Svingen PA; Grochow LB; Donehower RC; Rowinsky EK
    J Natl Cancer Inst; 1996 Jun; 88(11):734-41. PubMed ID: 8637027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A phase I study of weekly doxorubicin and oral topotecan for patients with relapsed or refractory small cell lung cancer (SCLC): A Fred and Pamela Buffet Cancer Center Clinical Trials Network study.
    Ernani V; Jahan R; Smith LM; Marr AS; Kimbrough SE; Kos ME; Tijerina J; Pivovar S; Lakshmanan I; Ketcham M; Rauth S; Mallya K; Nasser MW; Jain M; Kessinger A; Batra SK; Ganti AK
    Cancer Treat Res Commun; 2020; 22():100162. PubMed ID: 31675535
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Topotecan: a review of its efficacy in small cell lung cancer.
    Ormrod D; Spencer CM
    Drugs; 1999 Sep; 58(3):533-51. PubMed ID: 10493279
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Chloroquine enhances the cytotoxicity of topotecan by inhibiting autophagy in lung cancer cells.
    Wang Y; Peng RQ; Li DD; Ding Y; Wu XQ; Zeng YX; Zhu XF; Zhang XS
    Chin J Cancer; 2011 Oct; 30(10):690-700. PubMed ID: 21959046
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characterisation of a human small-cell lung cancer cell line resistant to the DNA topoisomerase I-directed drug topotecan.
    Sorensen M; Sehested M; Jensen PB
    Br J Cancer; 1995 Aug; 72(2):399-404. PubMed ID: 7640225
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The therapeutic inhibition of topoisomerase inhibitor and crizotinib combination in EGFR wild and mutant lung cancer cells.
    Liu Z; Li X; Gao J; Yin P; Teng Y; Yu P
    Biochem Pharmacol; 2022 Nov; 205():115294. PubMed ID: 36241099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Antiproliferation in human EA.hy926 endothelial cells and inhibition of VEGF expression in PC-3 cells by topotecan.
    Yang X; Zhang C; Ying M; Yang B; He Q
    Pharmazie; 2007 Jul; 62(7):534-8. PubMed ID: 17718196
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Postmarketing surveillance study on the use of topotecan in small-cell lung cancer. Use of topotecan in a pneumology university department].
    Hureaux J; Alizon C; Urban T
    Rev Mal Respir; 2012 May; 29(5):680-7. PubMed ID: 22682594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synergistic effect of combination topotecan and chronomodulated radiation therapy on xenografted human nasopharyngeal carcinoma.
    Zhang Y; Chen X; Ren P; Su Z; Cao H; Zhou J; Zou X; Fu S; Lin S; Fan J; Yang B; Sun X; Zhou Y; Chen Y; Yang L; Wu J
    Int J Radiat Oncol Biol Phys; 2013 Oct; 87(2):356-62. PubMed ID: 23906928
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Topotecan selectively enhances the radioresponse of human small-cell lung carcinoma and glioblastoma multiforme xenografts in nude mice.
    Chastagner P; Kozin SV; Taghian A
    Int J Radiat Oncol Biol Phys; 2001 Jul; 50(3):777-82. PubMed ID: 11395247
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan.
    Perez-Soler R; Glisson BS; Lee JS; Fossella FV; Murphy WK; Shin DM; Hong WK
    J Clin Oncol; 1996 Oct; 14(10):2785-90. PubMed ID: 8874340
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A phase I clinical trial of weekly oral topotecan for relapsed small cell lung cancer.
    Agelaki S; Kontopodis E; Kotsakis A; Chandrinos V; Bompolaki I; Zafeiriou Z; Papadimitraki E; Stoltidis D; Kalbakis K; Georgoulias V
    Cancer Chemother Pharmacol; 2013 Jul; 72(1):45-51. PubMed ID: 23604531
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Inhibition effect of topotecan on human myelodysplastic syndrome cells in vitro and in vivo].
    Liu JQ; Zhang WF; Jin J; Qian WB
    Zhejiang Da Xue Xue Bao Yi Xue Ban; 2006 Mar; 35(2):127-31. PubMed ID: 16610076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A Randomized Phase II Study of Linsitinib (OSI-906) Versus Topotecan in Patients With Relapsed Small-Cell Lung Cancer.
    Chiappori AA; Otterson GA; Dowlati A; Traynor AM; Horn L; Owonikoko TK; Ross HJ; Hann CL; Abu Hejleh T; Nieva J; Zhao X; Schell M; Sullivan DM
    Oncologist; 2016 Oct; 21(10):1163-1164. PubMed ID: 27694157
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Synergistic combination of DT-13 and topotecan inhibits human gastric cancer via myosin IIA-induced endocytosis of EGF receptor in vitro and in vivo.
    Yu XW; Lin S; Du HZ; Zhao RP; Feng SY; Yu BY; Zhang LY; Li RM; Qian CM; Luo XJ; Yuan ST; Sun L
    Oncotarget; 2016 May; 7(22):32990-3003. PubMed ID: 27105508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.